1. Home
  2. LCNB vs CDXS Comparison

LCNB vs CDXS Comparison

Compare LCNB & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LCNB Corporation

LCNB

LCNB Corporation

HOLD

Current Price

$15.97

Market Cap

234.5M

Sector

Finance

ML Signal

HOLD

Logo Codexis Inc.

CDXS

Codexis Inc.

HOLD

Current Price

$2.75

Market Cap

256.3M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
LCNB
CDXS
Founded
1877
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Major Chemicals
Sector
Finance
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
234.5M
256.3M
IPO Year
1999
2008

Fundamental Metrics

Financial Performance
Metric
LCNB
CDXS
Price
$15.97
$2.75
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
17.7K
1.4M
Earning Date
04-22-2026
05-07-2026
Dividend Yield
5.43%
N/A
EPS Growth
68.04
43.82
EPS
1.63
N/A
Revenue
$6,445,000.00
$138,590,000.00
Revenue This Year
$8.50
$7.73
Revenue Next Year
$3.66
$14.24
P/E Ratio
$9.71
N/A
Revenue Growth
N/A
32.30
52 Week Low
$13.75
$0.96
52 Week High
$17.89
$3.87

Technical Indicators

Market Signals
Indicator
LCNB
CDXS
Relative Strength Index (RSI) 43.50 64.71
Support Level $15.92 $2.37
Resistance Level $16.44 $2.83
Average True Range (ATR) 0.48 0.19
MACD -0.08 -0.02
Stochastic Oscillator 14.29 72.38

Price Performance

Historical Comparison
LCNB
CDXS

About LCNB LCNB Corporation

LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections, and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.

About CDXS Codexis Inc.

Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.

Share on Social Networks: